SOLICITATION NOTICE
66 -- 66- Fluorescence Upgrade package
- Notice Date
- 7/16/2003
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- RFQ-NCI-30029-NQ
- Response Due
- 7/23/2003
- Archive Date
- 8/7/2003
- Point of Contact
- Cynthia Brown, Purchasing Agent, Phone (301) 496-8608, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
cb106x@nih.gov, cr214i@nih.gov
- Description
- The National Cancer Institute (NCI), Laboratory of Cell Regulation and Carcinogenesis (LCRC), plans to procure a Fluorescence Package Upgrade for an existing laser capture microscopy system, from Arcturus Engineering Inc., 1220 Terra Bella Avenue, Mountain View, CA 94043. LCRC continues its strong tradition of emphasis on the study of the family of key regulatory peptides known as transforming growth factor-beta (TGF-beta), with focus on understanding both its basic biology, molecular biology, and biochemistry, as well as its roles in disease pathogenesis. Areas of research include identification of underlying mechanisms of epithelial carginogenesis in prostate, breast, gastric, and other cancers, with emphasis both on the dual tumor suppressive and oncogenic activities of TFG-beta, its receptors and hormonal regulation of prostate and breast cancer. The LRCR studies mechanism of signal transduction from the novel TFG-beta receptor serine-thereonine kinases, and the mechanisms of TFG-beta action in regulation of immune cell function, particularly as it relates to disease pathogenesis. The scope and breadth of the research in the LCRC provides a framework for integrating basic molecular and mechanistic studies with more complex animal model systems including transgenic and knock-out mice as well as conditional knock-out mice. Reccurence of breast cancer generally occurs after a long latent period and metastasis may become manifested a decade or more after primary treatement. The Molecular mechansm involved in the recurrence of breast cancer is largely unknown. Currently the only technology known to the NCI which is capable of performing such studies is through the use of laser capture microscopy (LCM) to obtain pure population of labeled metastaic cells in vivo. Arcturus Engineering is the only known source to the NCI that can provide the aforementioned fluorescent upgrade system for the existing LCM equipment. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requiremetns. Capability statements must be received in the contracting office by 1:30 PM EDT, (local Washington, D.C. time) on July 23, 2003. If you have any questions please contact Cynthia Brown, Purchasing Agent on (301) 402-4509. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considereed solely for the purpose of determining whether to conduct a competitive procurement. No collects calls will be accepted. The NAICS Code is 423450.
- Record
- SN00372653-W 20030718/030716213335 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |